Related Experiment Video
Updated: Jan 10, 2026
Peptide-based Identification of Functional Motifs and their Binding Partners
Published on: June 30, 2013
nNav1.5 mRNA Expression in Triple Negative and Non-Triple Negative Breast Cancer Patients Treated at Hospital Pakar
Ahmad Firdaus Ahmad Sukri1, Nuramira Syazreen Suhaimi1, Elis Rosliza Mohd Adzemi1
1Institute for Research in Molecular Medicine (INFORMM), Universiti Sains Malaysia, Health Campus, 16150 Kubang Kerian, Kelantan, Malaysia.
Objective:
This study aimed to evaluate the expression of nNav1.5 mRNA and its association with clinicopathological features in triple-negative breast cancer (TNBC) and non-TNBC patients treated at Hospital Pakar Universiti Sains Malaysia (HPUSM), Kelantan.
Methods:
Tumor tissue samples were collected from TNBC (n = 43) and non-TNBC (n = 19) patients. Real-time PCR was performed to measure nNav1.5 mRNA expression levels. Clinicopathological parameters assessed included tumor size, histological grade, cancer stage, hormone receptor status, HER2 expression, and lymph node involvement. Sanger sequencing was carried out to verify the identity of the amplified nNav1.5 transcripts.
Results:
nNav1.5 mRNA expression was significantly higher in TNBC compared to non-TNBC tumors (p = 0.007). Sanger sequencing confirmed >99% sequence identity with the canonical human nNav1.5 transcript. Elevated nNav1.5 expression was significantly associated with TNBC subtype (p = 0.007), advanced tumor stage (p = 0.007), and distant lymph node metastasis (p = 0.002).
Conclusion:
High expression of nNav1.5 mRNA in breast tumors is significantly associated with the TNBC subtype and aggressive clinical features.
